CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 33,512 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 33,512 shares of CeriBell stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $25.03, for a total value of $838,805.36. Following the completion of the sale, the chief financial officer directly owned 148,121 shares of the company’s stock, valued at $3,707,468.63. The trade was a 18.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Scott Blumberg also recently made the following trade(s):

• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Trading Down 2.3%

Shares of NASDAQ:CBLL opened at $24.31 on Friday. The stock has a market capitalization of $933.02 million, a price-to-earnings ratio of -13.81 and a beta of 0.81. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. The stock’s 50-day simple moving average is $19.43 and its two-hundred day simple moving average is $19.19. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.33.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The business had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $27.28 million. Analysts expect that CeriBell, Inc. will post -1.96 EPS for the current year.

Wall Street Analyst Weigh In

CBLL has been the topic of several recent research reports. BTIG Research increased their price target on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Barclays upgraded CeriBell to a “neutral” rating in a research note on Tuesday. Finally, Canaccord Genuity Group raised their target price on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $22.40.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in CeriBell during the 2nd quarter worth approximately $37,657,000. Vanguard Group Inc. boosted its position in shares of CeriBell by 11.1% in the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares during the period. KCM Capital Inc increased its stake in shares of CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after purchasing an additional 400,000 shares in the last quarter. Yu Fan increased its stake in shares of CeriBell by 10.7% in the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after purchasing an additional 130,964 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after purchasing an additional 1,162,200 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.